Director & Co Founder Fergus Magennis at Invoka Consulting explores how economic uncertainty is affecting organisations and the public sector, and how digital transformation can help.
David Hennell, the Business Development Director at National Broadband argues how county councils can immediately ensure high-quality broadband delivery to all constituents.
Chris Norman, the VP of Healthcare at Elcom highlights some of the issues hospitals and operating theatres are having with increasing patient safety and cutting costs.
Professor Robert Wille at the Technical University of Munich and the Software Competence Center Hagenberg discusses when quantum computing applications and knowledge are required – and, when not.
Michael Wuestefeld-Gray, the Managing Director at WuDo Solutions, explains the framework needed to generate effective Information Governance for organisations.
Marc Hoogstad, Head of Product Management at Finworks discusses removing data silos, implementing automation and gaining access to real-time data to encourage trusted data in government.
Chris Caton, product director – Commercial, at Ideal Heating, explains the impact that three low and zero-carbon heating technologies could have on decarbonising public sector buildings.
Chirag Karnik, Founder and Director at Neyo Ltd, guides us through IT solutions and Operations Management, and his vision for the future of the company.
Swiss inventor Francois Isaac de Rivaz created the world’s first internal combustion engine vehicle powered by hydrogen in 1807. Yet, hydrogen fuel cells have not become part of the mainstream fuel mix in mobility circles.
Ryo Nagase, Professor from Chiba Institute of Technology in Japan, highlights research concerning advancing connector technologies for multicore optical fibres, starting with an informative introduction.
Can the implementation of digital medication audits improve data transparency and accessibility, while reducing medication incidents and improving outcomes?
Efforts to prevent or treat Alzheimer’s Disease (AD) by targeting Amyloid beta (Aβ) assemblies should be continued, but the strategies should be altered dramatically.
